Salopyrine

Quick links to important sections

Salopyrine

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salopyrine

Property Description
Active ingredient Sulfasalazine
Form Enteric-coated tablet (oral), Suspension (oral)
Pharmacological class Disease-Modifying Antirheumatic Drug (DMARD)
General purpose Immunomodulation and control of chronic inflammation
Origin Synthetic compound (Prodrug)

Salopyrine, containing the active ingredient Sulfasalazine, is a prescription-only medicine primarily used to achieve long-term control over chronic inflammatory conditions. It is formally classified as a Disease-Modifying Antirheumatic Drug (DMARD), which distinguishes it from drugs that offer only temporary symptomatic relief. Its fundamental purpose is to modify the underlying disease process by modulating the immune response. Sulfasalazine is intended for use in systemic conditions requiring disease modification.


Salopyrine: Definition and Pharmacological Classification

Salopyrine is a synthetic DMARD belonging to the sulfonamide and aminosalicylate classes, designed to control long-term inflammation. As a DMARD, its role is to suppress the overactive components of the immune system that drive persistent tissue damage in chronic conditions. Chemically, Sulfasalazine is a complex molecule formed by linking the components sulfapyridine and 5-aminosalicylic acid (5-ASA) via an azo bond. The medicine provides systemic efficacy in modulating chronic inflammation.


What is Sulfasalazine Made Of? Composition and Form

The active ingredient, Sulfasalazine, is defined as a prodrug, meaning it is initially administered in an inactive form that must be metabolized to become active. Salopyrine is primarily available for oral administration as an enteric-coated tablet or a suspension. This enteric-coated form is engineered to be gastro-resistant, allowing the inactive prodrug to pass through the acidic environment of the stomach largely intact. This strategic delivery system ensures that the drug reaches the lower bowel, where specific bacterial enzymes cleave it into its active components, providing both localized anti-inflammatory effects (5-ASA) and systemic immunomodulation (sulfapyridine).


General Purpose: How Salopyrine Relates to Chronic Inflammation

The general therapeutic purpose of Salopyrine is to achieve a sustained reduction in the body's chronic inflammatory processes and immune hyperactivity. By acting as an immunomodulator and anti-inflammatory agent, the medicine helps to control and manage the persistent inflammation that leads to tissue stiffness, swelling, and pain. This foundational benefit relates to its role in reducing inflammatory markers and stems from its ability to interfere with immune cell function, providing a long-term strategy for modifying disease activity.

What side effects are possible with Salopyrine?

Possible side effects and safety information

The safety profile for Salopyrine (Sulfasalazine) is formally classified by regulatory authorities based on the frequency and system of the body affected. Reactions are grouped into categories such as Very Common, Common, Uncommon, and Rare, which reflect their documented incidence in clinical use.

Key adverse reactions are formally listed by the affected System-Organ Class (SOC). Common documented effects often involve the Gastrointestinal System (including nausea, vomiting, abdominal pain) and the Nervous System (including headache, dizziness). Effects on the Skin (rash, pruritus) are also frequently reported.

Serious Adverse Reactions

The official labeling highlights severe, potentially life-threatening risks. These include profound Blood Dyscrasias such as agranulocytosis and aplastic anemia, as well as severe systemic hypersensitivity events like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Fatal outcomes associated with serious hepatic (liver damage) and renal (kidney damage) toxicity are also documented.

Contextual Safety Patterns

The risk for certain serious reactions, particularly severe cutaneous events, is officially stated to be highest early in therapy, typically within the first month. Additionally, some side effects are dose-dependent, meaning a reduction in the prescribed amount may lead to relief. Reversible oligospermia and infertility are officially documented in males, with fertility typically returning after stopping the medicine.

Safety constraints mandate that Salopyrine is contraindicated in patients with conditions such as Porphyria or known hypersensitivity to sulfonamides or salicylates. Patients must maintain adequate fluid intake to prevent the formation of crystalluria and kidney stones.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Salopyrine (Sulfasalazine) is documented in regulatory labeling as a state of acute toxicity requiring immediate professional management.

Documented Manifestations and Severe Outcomes

Acute manifestations of overexposure commonly include nausea, vomiting, gastric distress, and abdominal pains. In more severe or advanced cases, drowsiness and convulsions may be observed. The severity of toxicity is directly related to elevated serum sulfapyridine concentrations. The most serious complication noted is the risk of complete renal blockage by crystals (crystalluria), which can lead to anuria (absence of urine production). Increased risk of severe toxicity exists for individuals with pre-existing hepatic or renal damage or blood dyscrasias.

Required Emergency Action

For any suspected overdosage, the official guidance mandates that you seek immediate medical attention or contact a poison control center at once. Management involves supportive and symptomatic treatment. Procedures described include gastric decontamination via gastric lavage or emesis, alkalinizing the urine, and regulating fluid intake based on kidney function. In cases of complete renal obstruction, specialized procedural interventions may be indicated. Monitoring includes measuring serum sulfapyridine concentrations to assess recovery.

Therapeutic Uses of Salopyrine

Main Therapeutic Uses of Salopyrine

Salopyrine is a medication primarily utilized for its analgesic and anti-inflammatory properties. It belongs to the salicylate class of drugs and is indicated for the management of conditions characterized by mild to moderate pain and inflammation.

Relief of Pain and Fever

Salopyrine is commonly used to address various types of acute and chronic pain. Its mechanism of action helps reduce the sensation of discomfort in several clinical contexts:

  • Headaches and Migraines: It can be used to alleviate common tension-type headaches and manage symptoms associated with migraine episodes.
  • Dental Pain: The medication is often employed to manage pain resulting from dental procedures or inflammatory conditions of the oral cavity.
  • Fever Reduction: As an antipyretic, it helps in lowering elevated body temperatures associated with common colds, influenza, or other febrile illnesses.

Management of Inflammatory Conditions

Due to its ability to inhibit inflammatory mediators, Salopyrine is frequently used in the treatment of musculoskeletal and joint disorders. It helps in reducing the swelling and stiffness associated with these conditions:

  • Rheumatoid Arthritis: It is used to manage the chronic inflammation and joint pain characteristic of this autoimmune condition.
  • Osteoarthritis: The medication helps relieve the pain associated with the gradual wear and tear of joint cartilage.
  • Neuralgia and Sciatica: Salopyrine may be used to treat nerve-related pain and inflammation, such as that affecting the sciatic nerve.

Benefits in Symptomatic Treatment

The primary benefit of Salopyrine lies in its dual action as both a pain reliever and an anti-inflammatory agent. By targeting the underlying inflammatory process, it provides symptomatic relief that can improve physical comfort. Its use is focused on stabilizing the patient's condition during acute flare-ups of chronic diseases or providing temporary relief from temporary physical ailments.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Salopyrine? (Sulfasalazine)

Official regulatory documents define strict population eligibility for Salopyrine, which is determined by age, allergies, and pre-existing medical conditions.

Populations Contraindicated (Must Not Use)

Salopyrine is contraindicated and must not be used by individuals with a documented hypersensitivity to sulfasalazine, its metabolites, sulfonamides, or salicylates. The medicine is also prohibited for patients with a diagnosis of porphyria or those with intestinal or urinary obstruction. Regulatory agencies universally prohibit its use in pediatric patients under two years of age for any indication.

Populations Approved and Restricted

Age Group / Condition Regulatory Eligibility Status
Adults (RA, UC) Approved for specific labeled indications.
Children (UC, PJIA) Approved for specific uses starting at 2 years (UC) and 6 years (PJIA).
Hepatic or Renal Impairment Use requires caution and close appraisal.
Pregnancy / Lactation Use only if clearly needed (pregnancy); use with caution (lactation).

Use is not recommended for children with systemic-onset Juvenile Idiopathic Arthritis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Salopyrine's interaction profile based on specific metabolic, absorption, and pharmacodynamic patterns. Co-administration with Methenamine is formally contraindicated due to the documented risk of crystalluria.

Documented Interaction Patterns

Interacting Substance Interaction Classification Official Outcome Description
Azathioprine / Mercaptopurine Enzyme-mediated (TPMT inhibition) Increases exposure to thiopurine metabolites and potential toxicity.
Digoxin Reduced absorption Reduces the absorption of Digoxin, risking non-therapeutic serum levels.
Folic Acid / Folate Supplements Reduced absorption/metabolism Inhibits absorption and metabolism of folic acid, leading to potential deficiency.
Methotrexate Pharmacodynamic Increased incidence of gastrointestinal adverse events when co-administered.
Oral Hypoglycemic Agents Pharmacodynamic reinforcement Potential for an increased risk of hypoglycemia.

These interactions are categorized by the regulatory bodies primarily based on a significant enzyme-mediated toxicity risk and changes in systemic exposure. The risk of adverse reactions related to the metabolite sulfapyridine is officially noted as higher in slow acetylator patients due to less efficient clearance.

Mechanism of Action

Salopyrine functions as a prodrug that undergoes azo bond cleavage by colonic bacteria in the lower bowel, releasing the active anti-inflammatory component, 5-aminosalicylic acid (5-ASA). This localized activation results in a high concentration of 5-ASA at the tissue surface. 5-ASA acts primarily as a non-selective inhibitor of both Prostaglandin G/H synthase (COX-1 and COX-2) and Polyunsaturated fatty acid 5-lipoxygenase (5-LOX). Inhibition of these enzymes within the Arachidonic Acid Pathway leads to a reduction in the synthesis of pro-inflammatory prostaglandins and leukotrienes.

Additionally, Salopyrine's mechanism extends to the Inhibitor of NF-kappaB kinase (IKK-beta) pathway. By interfering with IKK-beta, the drug suppresses the gene expression of pro-inflammatory cytokines and chemokines. This dual pathway modulation limits the activation and recruitment of immune cells, influencing the body's inflammatory signaling dynamics.

Dosage and Administration Information

Official Administration Guidelines

The administration of Salopyrine is structured around the oral route for systemic DMARD therapy, primarily utilizing 500 mg tablets and enteric-coated (delayed-release) tablets. The medicine requires a graduated dosing schedule to optimize patient tolerance. Treatment typically begins with a low initial dose which is then gradually titrated upward over several weeks to reach the long-term maintenance dose. For adult maintenance therapy in conditions like Rheumatoid Arthritis, the typical dose is 2 g daily, administered in two evenly divided doses. In contrast, the initial induction phase for Ulcerative Colitis may involve gradually increasing the dose up to 4 g per day.

Several practical conditions are required for proper use. The delayed-release tablets must be swallowed whole and must not be crushed, broken, or chewed, a restriction essential for ensuring the drug reaches the intended site of action in the lower bowel. Dosing is directed to occur preferably after meals, and patients must maintain adequate fluid intake throughout the day to support systemic function and minimize potential complications.

The overall use protocol is defined as long-term maintenance for disease management. For pediatric patients (aged six years and older), fixed dosing is replaced by a weight-based calculation (mg/kg/day) to determine the appropriate regimen. If a dose is missed, it should be taken as soon as possible unless the time for the next scheduled dose is imminent, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Salopyrine

Evidence for use in Type 2 Diabetes Mellitus

Research exploring Salopyrine in adults with Type 2 Diabetes Mellitus primarily involved large, well-structured Randomized Controlled Trials (RCTs). These studies were used to investigate measurements of markers of blood sugar control, like glycated hemoglobin (HbA1c) and fasting plasma glucose, over defined time intervals. The populations included those newly diagnosed or receiving common background medications.

Studies reported measurements of HbA1c and FPG that were reported to differ from comparator groups. Findings describe patterns where participants monitored in these trials had measured shifts in blood sugar markers, along with concurrent changes in body weight measurements. Limited data are available for populations with advanced kidney or liver conditions, and the long-term persistence of observed measurements is not fully established across all subgroups.


Evidence for use in Chronic Weight Management

Research for chronic weight management involved large-scale Randomized Controlled Trials that observed non-diabetic adults with overweight or obesity. These studies examined measurements of the percentage change in body weight and related health markers, such as blood pressure, over intermediate durations.

Findings describe patterns observed where participants who were monitored had percentage shifts measured in body weight that differed from the placebo groups. Research highlights concurrent changes measured in blood pressure and waist circumference. The evidence is limited regarding the long-term stability of the observed body weight measurements after the study period ends, and follow-up durations were limited relative to the chronic nature of obesity.


Evidence for the Reduction of Major Adverse Cardiovascular Events

The research examining cardiovascular outcomes involved specialized, long-term Cardiovascular Outcomes Trials (CVOTs). These studies monitored patients with Type 2 Diabetes and established cardiovascular disease or high risk. The primary focus was on monitoring the occurrence of a combined outcome of major events, including non-fatal heart attack, non-fatal stroke, and cardiovascular death.

The trials report that studies monitored the event rates of composite Major Adverse Cardiovascular Events (MACE) across the intervention and placebo groups over the study duration. Limited evidence is available regarding outcomes in individuals at low baseline cardiovascular risk. Further research is necessary to explore the patterns observed in the event rates.

Frequently Asked Questions (FAQ)

Common questions about Salopyrine (FAQ)


Q: How quickly does Salopyrine typically start to show an effect?

A: Official information identifies this medicine as a slow-acting treatment. Salopyrine is classified as a Disease-Modifying Anti-Rheumatic Drug (DMARD), which is descriptive of a medicine that functions gradually. It takes time to build up in the body and modify the underlying disease process, meaning an immediate clinical response is not expected.


Q: Does Salopyrine have a known risk of causing dependence?

A: According to official safety reports, this medicine is not associated with dependency. Regulatory documents state that Salopyrine is not known to cause physical dependence, drug abuse, or withdrawal symptoms.


Q: Can older adults use Salopyrine safely?

A: Official studies and guidelines suggest the medicine can be used by older adults. Dosage adjustments are generally not required for individuals over 65 years of age. Studies have observed that the medicine is generally well-tolerated across age groups, with similar measured outcomes and safety profiles in older adults compared to younger adults.


Q: Is Salopyrine a blood thinner?

A: No, Salopyrine is not classified as a blood thinner (anticoagulant). According to official definitions, its primary classification is as a Disease-Modifying Anti-Rheumatic Drug (DMARD) and an anti-inflammatory agent.


Q: Does Salopyrine affect driving ability?

A: Yes, official guidance warns that this medicine can cause side effects that impact the ability to drive. Salopyrine is known to cause dizziness, which is an effect on the nervous system. Official prescribing information states that using machinery or driving should be avoided if dizziness is experienced.


Q: How long does Salopyrine stay in your system?

A: Pharmacokinetic data provides measurements on how long the components stay in the body. The elimination half-life of the Salopyrine is typically between 5 to 10 hours. Its primary active component, sulfapyridine, can remain in the system longer, with a half-life ranging from approximately 6 to 14 hours depending on the individual’s metabolic rate.


Q: What kind of doctor typically prescribes Salopyrine?

A: The medicine is typically prescribed by specialists who treat its licensed indications. Since the drug is approved for chronic inflammatory conditions, prescribers are usually specialists like Rheumatologists (for arthritis) or Gastroenterologists (for inflammatory bowel conditions).


Q: What is the pregnancy category for Salopyrine?

A: The U.S. FDA has assigned this medicine a specific classification regarding use during pregnancy. Salopyrine is classified as Pregnancy Category B by the U.S. Food and Drug Administration.


Q: Can Salopyrine interact with common over-the-counter medications/supplements?

A: Official documents indicate that Salopyrine can affect how the body handles certain substances. The medicine may inhibit the absorption of folic acid (a B vitamin) and has been associated with an increased risk of low blood sugar when used alongside anti-diabetic medications. Official information also suggests that co-administering it with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may increase the likelihood of gastrointestinal side effects.


Q: Are there any specific lifestyle restrictions when taking Salopyrine?

A: Official safety information advises two main points regarding lifestyle. Regulatory documents state the importance of adequate fluid intake to support systemic function and help minimize the potential for kidney stones, a condition known as crystalluria. Furthermore, the medicine is associated with an increased risk of sensitivity to sunlight (photosensitivity), suggesting a need for sun protection.


Q: Does Salopyrine affect hormone levels?

A: Official labeling notes a documented, reversible effect on male fertility. This medicine can cause a temporary reduction in sperm count, medically known as oligospermia, which may lead to temporary infertility. Documentation notes that the adverse effect on fertility is generally reversible upon stopping the treatment.


Q: What happens when you stop taking Salopyrine?

A: Stopping the medicine can have two main documented outcomes related to its use. In males, the temporary low sperm count associated with treatment is known to be reversible. For chronic inflammatory conditions, official prescribing information describes that stopping maintenance treatment is associated with an increased likelihood of disease relapse.


Q: Are the side effects of Salopyrine generally temporary?

A: Not all effects are permanent, but official information provides context on when risks are highest. For example, the temporary low sperm count in males is known to be reversible. The risk for certain severe events, like serious allergic skin reactions, is officially stated to be highest during the first month of starting therapy.


Q: Why do I need regular lab tests when taking Salopyrine?

A: Official guidance mandates regular testing due to potential serious impacts on key organs. The medicine carries a documented risk for severe, life-threatening effects on the blood (such as agranulocytosis), liver, and kidneys. Therefore, to monitor these risks, tests like a Full Blood Count (FBC) and Liver and Kidney Function Tests (LFTs/RFTs) are frequently utilized.


Q: What makes Salopyrine different from other drugs in its class?

A: Official documentation highlights its unique status as a prodrug. This means the medication is administered in an inactive form that must be metabolized to become active. It relies on bacteria in the colon to cleave it into its two active components, 5-aminosalicylic acid (5-ASA) and sulfapyridine, which then act locally and systemically.


Q: Are there any studies on long-term side effects of Salopyrine after several years?

A: Evidence and clinical guidelines indicate a focus on organ function during long-term use. When taken for extended periods, prescribers typically monitor for potential effects on the kidneys, liver, and blood system. Consequently, regular blood monitoring is noted as a standard practice when the medicine is used for long durations.


Q: Are there any known interactions between Salopyrine and herbal remedies?

A: Regulatory authorities indicate that clinical data is limited for herbal remedies. There is not enough official clinical data to confirm the safety of using Salopyrine alongside most complementary medicines or herbal remedies. It is stated that individuals should discuss the use of any herbal product or supplement with a healthcare provider.


Q: Can Salopyrine affect sleep patterns?

A: While not commonly listed as a direct effect, the medicine is known to impact the nervous system. Official labeling for the medicine notes potential adverse effects like headache and dizziness. Although direct effects on sleep are not frequently reported, these central nervous system symptoms may indirectly impact a person's sleep patterns.

How should Salopyrine be stored and disposed of?

How to Store and Dispose of Salopyrine (Sulfasalazine)

The storage and disposal of Salopyrine must strictly follow conditions documented in the official regulatory labeling.

Storage Requirements

Salopyrine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from light and excessive moisture, and must not be frozen.

Handling and Safety

Tablets should be kept in the original container and the container must remain tightly closed. For safety, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. The medicine must not be thrown into wastewater or household waste to comply with environmental restrictions on pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salopyrine found in:

A-Z Index: